CSB 2.012 Note36. Alpha-pyrrolidinohexanophenone, commonly known as a-PHP.
CSB 2.012 Note37. 4-methyl-alpha-ethylainopentiophenone, commonly known as 4-MEAP.
CSB 2.012 Note38. 4’-methyl-alpha-pyrrolidinohexiophenone, commonly known as MPHP.
CSB 2.012 Note39. Alpha-pyrrolidinoheptaphenone, commonly known as PV8.
CSB 2.012 Note40. 4’-chloro-alpha-pyrrolidinovalerophenone, commonly known as 4-chloro-a-PVP.
CSB 2.012 HistoryHistory: cr. Affirmative action order under s. 961.11 (4g), Stats., Register August 2019 No. 764, eff. 8-19-19; CR 20-050: cr. Register June 2021 No. 786, eff. 7-1-21.
CSB 2.012 NoteCSB 2.69 Addition of Noroxymorphone to schedule II. Section 961.16 (2) (a) 10m., Stats., is created to read:
CSB 2.012 Note961.16 (2) (a) 10m. Noroxymorphone.
CSB 2.012 HistoryHistory: cr. Affirmative action order under s. 961.11 (4), Stats., Register November 2019 No. 767, eff. 11-11-19; CR 20-051: cr. Register June 2021 No. 786, eff. 7-1-21.
CSB 2.012 NoteCSB 2.70 Scheduling 4F-MDMB-BINACA and MMB-FUBICA. Section 961.14 (4) (tb) 38m. and 43m., Stats., are created to read:
CSB 2.012 Note961.14 (4) (tb) 38m. Methyl 2-(1-(4-fluorobutyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate, commonly known as 4F-MDMB-BINACA or 4F-MDMB-BUTINACA.
CSB 2.012 Note43m. Methyl 2-(1-(4-fluorobenzyl)-1H-indole-3-carboxamido)-3-methylbutanoate, commonly known as MMB-FUBICA or AMB-FUBICA.
CSB 2.012 HistoryHistory: EmR2017: emerg. cr., eff. 6-26-20; CR 20-022: cr. Register May 2021 No. 785, eff. 6-1-21.
CSB 2.012 NoteCSB 2.71 Addition of lasmiditan to schedule V. Section 961.22 (8), Stats., is created to read:
CSB 2.012 Note961.22 (8). Lasmiditan [2,4,6-trifluoro-N-(6-(1-methylpiperidine-4-carbonyl)pyridine-2-yl-benzamide].
CSB 2.012 HistoryHistory: cr. Affirmative action order under s. 961.11 (4), Stats., Register March 2020 No.771, eff. 3-23-20; CR 20-058: cr. Register July 2021 No. 787, eff. 8-1-21.
CSB 2.012 NoteCSB 2.72 Scheduling of isotonitazene and 1P-LSD. Section 961.14 (2) (pe) and (4) (jm), Stats., are created to read:
CSB 2.012 Note961.14 (2) (pe) Isotonitazene;
CSB 2.012 Note961.14 (4) (jm) 1-propionyl-lysergic acid diethylamide, commonly known as 1P-LSD;
CSB 2.012 HistoryHistory: EmR2013: emerg. cr., eff. 6-5-20; CR 20-023: cr. Register May 2021 No. 785, eff. 6-1-21; correction made under s. 35.17, Stats., Register May 2021 No. 785.
CSB 2.012 NoteCSB 2.73 Addition of cenobamate to schedule V. Section 961.22 (9), Stats., is created to read:
CSB 2.012 Note961.22 (9) CENOBAMATE Cenobamate ([(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate; 2H-tetrazole-2-ethanol, alpha-(2-chlorophenyl)-, carbamate (ester), (alphaR)-; carbamic acid (R)-(+)-1-(2-chlorophenyl)-2-(2H-tetrazol-2-yl)ethyl ester)
CSB 2.012 HistoryHistory: cr. Affirmative action order under s. 961.11 (4), Stats., Register May 2020 No. 773, eff. 5-18-20; CR 20-075: cr. Register July 2021 No. 787, eff. 8-1-21.
CSB 2.012 NoteCSB 2.74 Addition of Lemborexant to schedule IV. Section 961.20 (2) (eqm), Stats., is created to read:
CSB 2.012 Note961.20 (2) (eqm) Lemborexant.
CSB 2.012 HistoryHistory: cr. Affirmative action order under s. 961.11 (4), Stats., Register March 2020 No.771, eff. 5-18-20; CR 20-076: cr. Register July 2021 No. 787, eff. 8-1-21; correction made under s. 35.17, Stats., Register July 2021 No. 787.
CSB 2.012 NoteCSB 2.75 Exclusion of approved cannabidiol drugs from schedule I. (1) Section 961.14 (4) (t) 4., Stats., is created to read:
CSB 2.012 Note961.14 (4) (t) 4. A drug product in finished dosage formulation that has been approved by the United States food and drug administration that contains cannabidiol (2-[1R-3-methyl-6R-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol) derived from cannabis and no more than 0.1 percent (w/w) residual tetrahydrocannabinols.
CSB 2.012 Note(2)  Section 961.22 (7) is repealed.